CALL TO ORDER PRODUCTS
(800) 456-1477
MOMENTUM 3 is the largest LVAD trial ever conducted demonstrating excellent survival and safety outcomes with HeartMate 3™ LVAD.*1 The Continuing Access Protocol (CAP) was published in 2021 and extends the post-pivotal trial period for an additional 2 years in 1685 patients.2
At baseline, tested patients completed the 6-minute walk test at an average of 136 meters. At 2 years after HeartMate 3™ LVAD implant, patients completed the test at an average of 323 meters.1
MOMENTUM 3 Trial
*HeartMate 3 LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
**Key adverse events include pump thrombosis, stroke and gastrointestinal bleeding.
MAT-2012644 v3.0
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Precautions
Please be sure to read it.
The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.
The information provided here is not intended to provide information to patients and the general public.
Are you a healthcare professional?
Test
